Quick Takeaways
- BIOS Fund II, LP filed SCHEDULE 13D/A for IN8bio, Inc. Common Stock, par value $0.0001 per share (INAB).
- Disclosed ownership: 10%.
- Date of event: 02 May 2025.
BIOS Fund II, LP - 02 May 2025 SCHEDULE 13D/A Report for IN8bio, Inc. Common Stock, par value $0.0001 per share (INAB)
- Filing Manager
- BIOS Fund II, LP
- Reporting Manager
- BIOS CAPITAL MANAGEMENT, LP
- Symbol
- INAB
- Shares outstanding
- 91,292,022 shares
- Disclosed Ownership
- 9,120,073 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13D/A
- Filing time
- 08 May 2025, 17:53:02 UTC
- Date of event
- 02 May 2025
- Next filing
- 29 Dec 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BIOS Fund II, LP disclosed 10% ownership in IN8bio, Inc. Common Stock, par value $0.0001 per share (INAB) on 02 May 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 08 May 2025, 17:53.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (19)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BIOS FUND II, LP | 0.6% | 574,432 | 0 | 574,432 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001714576 |
| BIOS FUND II QP, LP | 2.1% | 1,876,624 | 0 | 1,876,624 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001716869 |
| BIOS FUND II NT, LP | 0.3% | 251,211 | 0 | 251,211 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001728851 |
| BIOS INCYSUS CO-INVEST I, LP | 1.1% | 997,433 | 0 | 997,433 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001740029 |
| BIOS FUND III, LP | 0.6% | 570,724 | 0 | 570,724 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001791917 |
| BIOS FUND III QP, LP | 4.1% | 3,727,597 | 0 | 3,727,597 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001791916 |
| BIOS FUND III NT, LP | 0.7% | 601,980 | 0 | 601,980 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001791910 |
| BIOS CLINICAL OPPORTUNITY FUND, LP | 3.3% | 3,140,803 | 3,140,803 | 0 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001988639 |
| BP DIRECTORS, LP | 0.1% | 121,775 | 0 | 121,775 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813311 |
| BIOS EQUITY PARTNERS, LP | 0.1% | 121,775 | 0 | 121,775 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813314 |
| BIOS EQUITY PARTNERS II, LP | 4.1% | 3,699,700 | 0 | 3,699,700 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813313 |
| BIOS EQUITY PARTNERS III, LP | 5.4% | 4,900,301 | 0 | 4,900,301 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001831976 |
| BIOS EQUITY COF, LP | 3.3% | 3,140,803 | 3,140,803 | 0 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0002000747 |
| CAVU MANAGEMENT, LP | 9.6% | 8,721,776 | 0 | 8,721,776 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813270 |
| BIOS CAPITAL MANAGEMENT, LP | 10% | 9,120,073 | 0 | 9,120,073 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813845 |
| CAVU ADVISORS, LLC | 9.6% | 8,721,776 | 0 | 8,721,776 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813310 |
| BIOS ADVISORS GP, LLC | 9.9% | 9,120,073 | 0 | 9,120,073 | /s/ Daniel Schwarz | Daniel Schwarz/Attorney-in-Fact | 0001813844 |
| LESLIE W. KREIS | 9.6% | 8,721,776 | 0 | 8,721,776 | /s/ Daniel Schwarz | DANIEL SCHWARZ, as Attorney-in-Fact for Leslie W. Kreis, Jr. | 0001813316 |
| AARON G.L. FLETCHER | 10% | 9,120,073 | 0 | 9,120,073 | /s/ Daniel Schwarz | DANIEL SCHWARZ, as Attorney-in-Fact for Aaron G.L. Fletcher | 0001789490 |